TriSalus Life Sciences® Inc. has announced the launch of the TriNav® FLX Infusion System, marking a significant advancement in their TriNav portfolio. This new system retains the trusted Pressure-Enabled Drug DeliveryTM benefits but introduces a design enhancement with twice the length of more flexible material at the distal end, improving navigation through challenging vascular pathways. In benchtop models, the TriNav FLX demonstrated a 28% reduction in force during navigation compared to the standard design. The system is also eligible for reimbursement under HCPCS codes C8004 and C9797, allowing for both planning and treatment procedures. This innovation aims to enhance the capabilities of Interventional Radiologists in treating patients with complex peripheral vessel anatomy.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.